Setting up labs is hard, and highly specialised experts are wasting up to 80% of their time on it. Inefficiencies in this area directly impact R&D and can mean the difference between a vaccine being released on time or not. 

Global R&D spend has reached US$1.7T, yet biotech companies are still purchasing equipment through lengthy interactions with sales reps, with no upfront price or lead time transparency. Celerity is changing the way this is done to make lab setup a matter of weeks, not months, by automating the manual processes involved in the procurement journey. Celerity also promotes a more sustainable approach to lab builds by making the second-hand market more accessible, having already saved its customers over US$10K in spending.